Related Experiment Video
Updated: Apr 21, 2026
10:03
A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
Published on: February 28, 2013
25.3K
Type 2 diabetes pharmacoepidemiology update 2014: safety versus efficacy
1Johns Hopkins University School of Medicine, E7144, 624 N Wolfe St, Baltimore, MD, 21287, USA, ssingh31@jhu.edu.
Current Diabetes Reports
|November 4, 2014
Summary
New type 2 diabetes medications effectively lower blood sugar, but none have proven cardiovascular benefits. Emerging safety concerns for some drugs require further investigation.
Area of Science:
- Endocrinology
- Pharmacology
- Public Health
Background:
- The therapeutic landscape for type 2 diabetes has expanded significantly with new drug classes.
- Current treatments include insulins, metformin, sulfonylureas, thiazolidinediones, incretin-based therapies, and SGLT2 inhibitors.
Purpose of the Study:
- To review the safety and efficacy of current type 2 diabetes medications.
- To highlight updated findings on drug performance and emerging safety signals.
Main Methods:
- Review of recent scientific literature and clinical trial data.
- Analysis of pharmacoepidemiological evidence regarding drug safety and efficacy.
Main Results:
- Most type 2 diabetes agents achieve a 0.8-1.5% reduction in glycated hemoglobin.
- No medication has demonstrated cardiovascular risk reduction in clinical trials.
- Potential safety concerns include thiazolidinediones linked to bladder cancer and incretins to pancreatic cancer.
Conclusions:
- While effective for glycemic control, current type 2 diabetes drugs have limitations in cardiovascular risk reduction.
- Ongoing pharmacoepidemiological research is crucial for understanding long-term safety and efficacy.
- Further studies are needed to confirm emerging safety signals for specific drug classes.
More Related Videos
07:30Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
8.2K
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
1.1K
Related Concept Videos
01:24Type II Diabetes II: Pathophysiology
6
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
6
01:22Diabetes Mellitus: Type 2 and Gestational
4.8K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.8K
01:15Diabetes: Management and Pharmacotherapy
1.5K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K
01:26Type II Diabetes I: Introduction
5
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
5
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
622
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
622
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
982
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
982